Rayonier Advanced Materials Announces Second Quarter 2017 Dividend

JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Rayonier Advanced Materials Inc. (NYSE: RYAM) announced today that the Company’s board of directors has declared a second quarter cash dividend of $0.07 per share of common stock of the Company. The dividend is payable on June 30, 2017 to holders of common stock of record on June 16, 2017.

About Rayonier Advanced Materials

Rayonier Advanced Materials is the leading global supplier of high-purity, cellulose specialties natural polymers for the chemical industry. Working closely with its customers, the Company engineers natural polymeric chemical chains to create dozens of customized high-purity performance fibers at its plants in Florida and Georgia. Rayonier Advanced Materials’ intellectual property and manufacturing processes have been developed over 90 years, resulting in unique properties and very high quality and consistency. The Company’s facilities have the capacity to produce approximately 485,000 tons of cellulose specialties for use in a wide range of industrial and consumer products such as filters, cosmetics and pharmaceuticals and approximately 245,000 tons of commodity products. Rayonier Advanced Materials is consistently ranked among the nation’s top 50 exporters and delivers products to 80 ports around the world, serving customers in 35 countries across five continents. More information is available at www.rayonieram.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170523006243/en/

Rayonier Advanced Materials Inc.
Media:
Randy Houck, 904-357-9134
or
Investors:
Mickey Walsh, 904-357-9162

Source: Rayonier Advanced Materials Inc.

You May Also Be Interested In

• NBME Selects Suzanne T. Anderson, MBA, as the Next President and Chief Executive Officer
• Vero Fiber's Fiber-To-The-Home Services Go Live
• LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer